Danazol for uterine fibroids.
BACKGROUND
Uterine fibroids (myomas, fibromyomas, leiomyomas) are the most common benign tumours of the female genital tract. Danazol, a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone, has been used for many years for the treatment of women with uterine fibroids.


OBJECTIVE
To evaluate the effectiveness and safety of danazol in women with uterine fibroids.


METHODS
We searched the Cochrane Menstrual Disorders and Subfertility Review Group Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4); MEDLINE; EMBASE; Chinese Biomedical Disc; and the China National Knowledge Infrastructure for relevant trials (to December 2008). Attempts were made to identify trials from references in published studies. We also searched for ongoing trials in the five major clinical trials registries.


METHODS
Randomised controlled trials of danazol versus placebo or any other medical therapy in women with uterine fibroids confirmed by medical procedures, regardless of the women's symptoms or age. Women with malignancies were excluded.


METHODS
Data extraction and risk of bias assessment were not been performed because there were no identified studies.


RESULTS
We did not identify any studies which met our full inclusion criteria.


CONCLUSIONS
There is no reliable evidence available from randomised controlled trials regarding the benefits and or harms of the use of danazol for treating uterine fibroids.
Ke
Lin-Qiu
LQ
West China Medical School of Sichuan University, South of Renmin Road 17#, Chengdu, China.
Yang
Kun
K
Li
Jing
J
Li
Chun-Mei
CM
D003613:Danazol / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004965:Estrogen Antagonists; D003613:Danazol